Repare Therapeutics Competitors

Atea Pharmaceuticals (NASDAQ:AVIR) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Atea Pharmaceuticals and Repare Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Atea Pharmaceuticals and Repare Therapeutics, as provided by MarketBeat.com.

Atea Pharmaceuticals currently has a consensus target price of $69.3333, suggesting a potential upside of 25.35%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Repare Therapeutics.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Atea Pharmaceuticals and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Repare Therapeutics beats Atea Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Biohaven Pharmaceutical and Repare Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biohaven Pharmaceutical and Repare Therapeutics, as provided by MarketBeat.com.

Biohaven Pharmaceutical currently has a consensus target price of $96.4545, suggesting a potential upside of 36.29%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Biohaven Pharmaceutical's higher probable upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Repare Therapeutics.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 64.8% of Repare Therapeutics shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Sage Therapeutics (NASDAQ:SAGE) and Repare Therapeutics (NASDAQ:RPTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sage Therapeutics and Repare Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Sage Therapeutics and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Repare Therapeutics has lower revenue, but higher earnings than Sage Therapeutics.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sage Therapeutics and Repare Therapeutics, as provided by MarketBeat.com.

Sage Therapeutics currently has a consensus target price of $87.0625, suggesting a potential upside of 16.58%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 21.38%. Given Repare Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Sage Therapeutics.

Summary

Repare Therapeutics beats Sage Therapeutics on 7 of the 10 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Hutchison China MediTech's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Repare Therapeutics and Hutchison China MediTech's revenue, earnings per share and valuation.

Repare Therapeutics has higher earnings, but lower revenue than Hutchison China MediTech.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Hutchison China MediTech, as reported by MarketBeat.

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 36.52%. Given Hutchison China MediTech's higher possible upside, analysts clearly believe Hutchison China MediTech is more favorable than Repare Therapeutics.

Summary

Repare Therapeutics beats Hutchison China MediTech on 3 of the 5 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Emergent BioSolutions' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Repare Therapeutics and Emergent BioSolutions' revenue, earnings per share and valuation.

Emergent BioSolutions has higher revenue and earnings than Repare Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Emergent BioSolutions, as reported by MarketBeat.

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Emergent BioSolutions has a consensus price target of $109.8333, suggesting a potential upside of 44.78%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Repare Therapeutics.

Summary

Emergent BioSolutions beats Repare Therapeutics on 7 of the 9 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Repare Therapeutics and Arena Pharmaceuticals' revenue, earnings per share and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Repare Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Arena Pharmaceuticals, as reported by MarketBeat.

Repare Therapeutics presently has a consensus price target of $39.40, suggesting a potential upside of 21.38%. Arena Pharmaceuticals has a consensus price target of $91.80, suggesting a potential upside of 41.75%. Given Arena Pharmaceuticals' higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Repare Therapeutics.

Summary

Arena Pharmaceuticals beats Repare Therapeutics on 5 of the 8 factors compared between the two stocks.